Everence Capital Management Inc Lowers stake in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : Everence Capital Management Inc reduced its stake in Eli Lilly and Co by 7.98% during the most recent quarter end. The investment management company now holds a total of 31,595 shares of Eli Lilly and Co which is valued at $2,613,538 after selling 2,740 shares in Eli Lilly and Co , the firm said in a disclosure report filed with the SEC on Aug 1, 2016.Eli Lilly and Co makes up approximately 0.78% of Everence Capital Management Inc’s portfolio.

Other Hedge Funds, Including , Lourd Capital boosted its stake in LLY in the latest quarter, The investment management firm added 498 additional shares and now holds a total of 3,811 shares of Eli Lilly and Co which is valued at $315,246. Eli Lilly and Co makes up approx 0.09% of Lourd Capital’s portfolio.First Citizens Bank Trust Co reduced its stake in LLY by selling 172 shares or 2.83% in the most recent quarter. The Hedge Fund company now holds 5,902 shares of LLY which is valued at $489,217. Eli Lilly and Co makes up approx 0.04% of First Citizens Bank Trust Co’s portfolio.Louisiana State Employees Retirement System reduced its stake in LLY by selling 1,400 shares or 2.15% in the most recent quarter. The Hedge Fund company now holds 63,700 shares of LLY which is valued at $5,312,580. Eli Lilly and Co makes up approx 0.27% of Louisiana State Employees Retirement System’s portfolio.Checchi Capital Advisers reduced its stake in LLY by selling 703 shares or 5.59% in the most recent quarter. The Hedge Fund company now holds 11,870 shares of LLY which is valued at $968,473. Eli Lilly and Co makes up approx 0.24% of Checchi Capital Advisers’s portfolio.

Eli Lilly and Co closed down -0.3 points or -0.36% at $82.42 with 20,93,793 shares getting traded on Thursday. Post opening the session at $83.02, the shares hit an intraday low of $82.37 and an intraday high of $83.02 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.

Investors should note that on Jun 20, 2016, Eli Lilly and Co announced a cash dividend of $0.5100. The company’s management has announced Aug 11, 2016 as the ex-dividend date and fixed the record date on Aug 15, 2016. The payable date has been fixed on Sep 9, 2016.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.